@dansfera: The strategy of building a research site to be acquired is shifting. This perspective highlights how diversifying clinical trial capabilities and locations creates irresistible value for buyers. But beyond the numbers, it’s about the exit strategy: selling doesn't have to mean walking away and leaving the team behind. When structured correctly—protecting employees and securing their future—it’s a masterclass in business growth and the true spirit of capitalism. Whether you're building to hold or building to sell, the ultimate goal is creating something sustainable enough to have that choice. #clinicaltrials #researchsite #businessgrowth #acquisitions #biotech

132

There are no more comments for this video.

To see more videos from user @dansfera, please go to the Tikwm homepage.